Despite a poor return on investment thus far, innovations in high-throughput screening are still very much in demand.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
High content screening for drug discovery from traditional Chinese medicine
Chinese Medicine Open Access 28 February 2019
-
Systematic error detection in experimental high-throughput screening
BMC Bioinformatics Open Access 19 January 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout


Source: Recombinant Capital

Image courtesy of Akceli.

Image courtesy Phylonix.
References
Dove, A. Drug screening—beyond the bottleneck. Nat. Biotechnol. 17, 859–863 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dove, A. Screening for content—the evolution of high throughput. Nat Biotechnol 21, 859–864 (2003). https://doi.org/10.1038/nbt0803-859
Issue Date:
DOI: https://doi.org/10.1038/nbt0803-859
This article is cited by
-
High content screening for drug discovery from traditional Chinese medicine
Chinese Medicine (2019)
-
Systematic error detection in experimental high-throughput screening
BMC Bioinformatics (2011)
-
High-content analysis in neuroscience
Nature Reviews Neuroscience (2008)
-
Lab-on-a-chip: microfluidics in drug discovery
Nature Reviews Drug Discovery (2006)
-
Statistical practice in high-throughput screening data analysis
Nature Biotechnology (2006)